Eisai (OTCMKTS:ESALY) and Jungheinrich (OTCMKTS:JGHAF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.
Eisai pays an annual dividend of $0.62 per share and has a dividend yield of 0.6%. Jungheinrich does not pay a dividend. Eisai pays out 38.0% of its earnings in the form of a dividend.
This is a summary of current ratings and recommmendations for Eisai and Jungheinrich, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider & Institutional Ownership
0.1% of Eisai shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Eisai has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Comparatively, Jungheinrich has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
This table compares Eisai and Jungheinrich’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Eisai and Jungheinrich’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eisai||$5.42 billion||5.26||$466.60 million||$1.63||58.95|
Eisai has higher revenue and earnings than Jungheinrich.
Eisai beats Jungheinrich on 7 of the 10 factors compared between the two stocks.
Eisai Company Profile
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. It offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer's disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment. The company also provides Lunesta, a non-benzodiazepine hypnotic agent for insomnia treatment; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; and epilepsy franchise products, including Zonegran, Zebinix, Fycompa, and Inovelo, which are antiepileptic agents. In addition, it offers Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome; Actonel, an osteoporosis treatment; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. The company has strategic partnerships with Quintiles Inc. for developing six types of anticancer compound candidates; and Epizyme, Inc. to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically defined patients. It also has collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop Lenvima (lenvatinib mesylate), a multi-kinase inhibitor, as well as Opdivo, a human anti-human programmed cell death-1 monoclonal antibody, for the treatment of hepatocellular carcinoma; and Merck & Co., Inc. to develop and commercialize Lenvima. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Jungheinrich Company Profile
Jungheinrich Aktiengesellschaft, through its subsidiaries, manufactures and supplies products in the fields of forklift trucks, and warehousing and material flow technology. The company's Intralogistics segment develops, produces, sells, and rents new material handling equipment and warehousing technology products; sale and short-term leasing of new and used equipment; and provides spare parts, as well as maintenance and repair services. Its Financial Services segment engages in the sales financing and usage transfer of forklifts and warehousing technology products. The company offers new forklifts, such as pallet trucks, order pickers, reach trucks, high rack stackers, forklift trucks, tow tractors, trailers, and shuttles; counterbalanced forklift trucks; and automated components, including automated guided vehicles, conveyor systems, and stacker cranes. It also provides batteries, electric drives/drivetrains, controllers, electro mechanic components/control pedals/displays, electric mounting panels, and cable sets; and develops software solutions. The company distributes its products through its direct sales and service network, as well as through dealers and mail orders in Germany and internationally. Jungheinrich Aktiengesellschaft was founded in 1953 and is headquartered in Hamburg, Germany.
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.